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The HIV-1 Nef protein causes a decrease in major histocompatibility complex (MHC) class I and CD4 molecule expression on the cell
surface. To determine if Nef can affect components of the innate immune response, we assessed the ability of Nef to alter the cell surface
expression of human CD1d. In cells co-expressing CD1d and Nef, a substantial reduction in the cell surface level of CD1d was observed, with
a concomitant reduction in the activation of CD1d-restricted NKT cells. Nef had a minimal effect on the cell surface expression of a mutant
CD1d molecule in which the last 6 or 10 amino acids of the cytoplasmic tail were deleted. Additionally, it was found that Nef physically
interacted with wild-type (but not tail-deleted) CD1d. Therefore, one means by which HIV-1 may be able to establish a foothold in an infected
individual is by directly interfering with the functional cell surface expression of CD1d.
D 2005 Elsevier Inc. All rights reserved.Keywords: CD1d; Human; Murine; HIV-1; Nef; Cell surface expression; ComplexIntroduction
Among the proteins expressed after an HIV infection, the
myristylated 27–35 kDa Nef molecule is detected in
abundance soon after infection and has multiple functions.
Several studies have shown that Nef affects cellular signal
transduction pathways, inhibits apoptosis, enhances virion
infectivity, and reduces cell surface expression of HLA class
I (HLA-A and HLA-B) and class II molecules, as well as
CD4 (Geleziunas et al., 2001; Le Gall et al., 1998; Lu et al.,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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1 These two authors contributed equally.1998; Mahlknecht et al., 2000; Sol-Foulon et al., 2002;
Stumptner-Cuvelette et al., 2001). However, Nef does not
inhibit the expression of HLA-C and HLA-E molecules,
which are necessary for protection from natural killer (NK)
cell-mediated lysis (Le Gall et al., 1998). The mechanism of
the Nef-mediated reduction in CD4 cell surface expression
involves an increase in endocytosis, linking of the CD4 tail
with cellular trafficking/adaptor molecules (adaptor protein-
2, AP-2; v-ATPase) and the targeting of CD4 molecules to
lysosomes (Lu et al., 1998). There, a dileucine motif in the
CD4 tail was identified as important for Nef’s function. In
the downregulation of MHC class I molecules, Nef is
responsible for their retention in the trans-Golgi network
(TGN) by interacting with adaptor protein-1 (AP-1) and
PACS-1-associated MHC class I (Le Gall et al., 1998;
Piguet et al., 2000). Parallel to the observation with CD4, a05) 242 – 252
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important for its downregulation by Nef (Le Gall et al.,
1998).
HIV-1 is known to infect CD4+ T cells, dendritic cells,
and macrophages (Stebbing et al., 2004), although it has
been suggested that CD4+ T cells are a primary reservoir of
the virus, at least initially (Stahl-Hennig et al., 1999; Veazey
et al., 1998). CD4 (primary receptor) and chemokine
receptor (co-receptor) expression are both required for
HIV entry into target cells (Moore et al., 1997). CCR5 is
the major co-receptor on macrophages for HIV-1 and simian
immunodeficiency virus (SIV) strains (‘‘R5 tropic’’).
Recently, CD4+ natural killer T (NKT) cells, a unique
population of T cells that have an invariant T cell receptor
(TCR) a chain rearrangement (Va24Ja18 in humans;
Va14Ja18 in mice), and recognize the non-polymorphic
MHC class I-like lipid antigen-presenting molecule, CD1d
(Kronenberg and Gapin, 2002; Taniguchi et al., 2003), have
been shown to be infected by R5-tropic HIV-1 (Fleuridor et
al., 2003; Motsinger et al., 2002; Sandberg et al., 2002; van
der Vliet et al., 2002). HIV-1 replicated to much higher
levels in CD4+ NKT cells than in mainstream CD4+ T cells,
resulting in the former’s death (Motsinger et al., 2002). The
susceptibility of CD4+ NKT cells to R5-tropic HIV
infections is thus due to the cell surface expression of both
CCR5 and CD4 molecules (Sandberg et al., 2002). This
HIV-1-induced loss of NKT cells is reminiscent of a similar
loss in mice infected with LCMV, previously reported by
our laboratory (Hobbs et al., 2001). For the activation of
NKT cells, CD1d molecules are required to traffic through
intracellular compartments of the endocytic pathway (Brut-
kiewicz et al., 2003). Unlike MHC class II molecules, which
use sequences in the invariant chain to traverse the
endocytic pathway, CD1d molecules use a tyrosine-based
endosomal targeting motif (YXXZ, X = any amino acid and
Z = a hydrophobic amino acid) in the cytoplasmic tail
(Moody and Porcelli, 2003), although human and mouse
CD1d have been shown to be associated with invariant
chain (Jayawardena-Wolf et al., 2001) and/or MHC class II
molecules (Kang and Cresswell, 2002). In addition, humanFig. 1. An HIV-1 infection causes a reduction in the cell surface expression of hum
the NL4-3 strain of HIV-1 for 8 days. For the last 3 days of culture, 3 Ag/ml of P
specific for CD1d in mock (open histogram)- or HIV-1-infected (filled histogram) J
2-treated and untreated Jurkat (data not presented). Analysis was by FACS.(but not mouse) CD1d molecules contain a C-terminal
dileucine-like motif (Rodionov et al., 1999, 2000).
An HIV-1 infection is known to target and alter the
expression of MHC class I molecules on antigen presenting
cells through the action of Nef (Collins, 2004). However, the
effect of an HIV-1 infection on CD1d molecules has not been
thoroughly studied. Our results suggest that HIV-1 Nef
physically forms a complex with CD1d, causing its down-
regulation from the cell surface, illustrating an important
means by which HIV-1 may establish an early foothold in the
infected host.Results
HIV-1 decreases hCD1d surface expression upon infection
It has been shown that HIV-1 can cause the down-
regulation of MHC class I (Collins, 2004) and MHC class II
molecules (Stumptner-Cuvelette et al., 2001). However, it is
not known if an HIV-1 infection results in a decrease in
CD1d. Thus, in order to determine if cell surface levels of
CD1d are affected by an HIV-1 infection, we infected the
CD1d+ human Jurkat T cell line (Gansuvd et al., 2002;
Metelitsa et al., 2001, 2003) with the NL4-3 strain of HIV-1
for 8 days, and assessed the cell surface level of CD1d by
FACS. As shown in Fig. 1, Jurkat cells infected with HIV-1
had significantly less cell surface CD1d than mock-infected
cells. Other strains of HIV-1 (e.g., IIIB strain) caused a
similar reduction in CD1d on Jurkat and another human
CD1d+ T cell line, MOLT-4 (data not shown). Therefore,
upon infection with HIV-1, the cell surface level of CD1d is
substantially reduced.
Reduction in hCD1d surface expression by HIV-1 Nef
As it was shown above that an HIV-1 infection of Jurkat
cells resulted in a reduction in hCD1d surface expression,
and because the HIV-1 Nef protein can inhibit the expression
of MHC class I (Collins, 2004; Collins et al., 1998) and classan CD1d. The human Jurkat T cell line was infected with 1  103 TCID50 of
HA was added. The cells were then stained with a PE-conjugated antibody
urkat cells. Reductions in CD1d were also observed with HIV-1-infected IL-
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asked whether Nef could cause a reduction in CD1d
observed in HIV-1-infected Jurkat cells (Fig. 1). To address
this question, human T2 cells (DeMars et al., 1984; Salter
and Cresswell, 1986) were coinfected with rVV encoding
HLA-A2.1 or human CD1d, and HIV-1 Nef (or a control
rVV) overnight at an MOI of 5. Cell surface expression of
HLA-A2.1 and CD1d was analyzed by FACS. Because it is
also well known that HIV-1 Nef can reduce CD4 levels upon
expression (Aiken et al., 1994), cell surface staining for CD4
was also assessed. As previously reported (Collins, 2004;
Collins et al., 1998), co-expression of Nef with MHC class I
molecules resulted in a substantial (57.6%) decrease in the
cell surface levels of the latter (Fig. 2). Likewise, CD4 levels
were comparably reduced (60.5%). As was observed with a
natural HIV-1 infection (Fig. 1), the cell surface level of
CD1d in cells co-expressing HIV-1 Nef was inhibited by
over 70% (Fig. 2). Therefore, these results suggest that the
HIV-1 Nef protein can substantially impair the cell surface
expression of hCD1d.
Cell surface murine CD1d1 expression is reduced by
HIV-1 Nef
The murine CD1d1 molecule is the mouse homologue to
human CD1d (Porcelli and Modlin, 1999) and has been
shown to share close functional homology as well (BrossayFig. 2. HIV-1 Nef impairs the cell surface expression of hCD1d. Human T2 cells
Nef (or a control rVV) at an MOI of 5 (for each virus) for 12 h at 37 -C. The cells w
HLA-A2.1 expression was revealed by staining with W6/32 followed by a PE-coet al., 1998; Exley et al., 1997). Thus, it was asked whether
the HIV-1 Nef molecule could cause a reduction in the cell
surface level of CD1d1 as in the human homologue. For
this experiment, murine P13.9 fibroblasts were infected
with rVV encoding CD1d1 (Brutkiewicz et al., 1995) or H-
2Db (Prasad et al., 1998), in the presence of a control rVV,
or rVV encoding Nef or the MCMV protein m06. The m06
protein has been shown to inhibit murine MHC class I cell
surface expression (Reusch et al., 1999) in a similar manner
as Nef affects human HLA class I molecules (Collins and
Baltimore, 1999); the resultant effect by both of these
immunoevasins is impaired CTL generation (Collins et al.,
1998; Krmpotic et al., 2002). The cell surface levels of
CD1d1 and Db were then analyzed by FACS. As expected,
the m06 protein caused a substantial (58.0%) reduction in
the cell surface expression of Db (Fig. 3). In contrast, m06
co-expression only caused a slight reduction in CD1d1.
Interestingly, co-expression of the HIV-1 Nef protein
caused a 46.0% and 37.2% decrease, respectively, in
CD1d1 and Db on the cell surface (Fig. 3). The latter
finding is consistent with Nef not being able to decrease
murine MHC class I molecules to the same degree as
human HLA class I antigens (Fleis et al., 2002). Therefore,
the HIV-1 Nef protein can also impair the cell surface
expression of murine CD1d1 molecules, suggesting that
Nef targets an evolutionarily conserved aspect of all CD1d
molecules.were infected with rVV encoding HLA-A2.1 or wild-type hCD1d with VV-
ere then stained with PE-conjugated antibodies specific for CD4 or hCD1d.
njugated rabbit anti-mouse antiserum. Analysis was by FACS.
Table 1
Recombinant VV (rVV) expressing wildtype and mutant hCD1d molecules
generated for this study
rVV Cytoplasmic Tail
Sequence
Wildtype SRFKRQTSYQGVL
Y331F SRFKRQTSFQGVL
Y331A SRFKRQTSAQGVL
TD-6 SRFKRQT
TD-10 SRF
L335A SRFKRQTSYQGVA
V334A/L335A SRFKRQTSYQGAA
Y331F/L335A (YFLA) SRFKRQTSFQGVA
Fig. 3. HIV-1 Nef impairs the cell surface expression of the murine CD1d1 molecule. Murine P13.9 fibroblasts were infected with rVVencoding HIV-1 Nef, the
MCMV protein m06, or a control rVV, and rVV expressing mCD1d1 or H2-Db at an MOI of 3 for 12 h at 37 -C. The cells were then stained with PE-labeled
antibodies specific for mCD1d (top panels) or Db (bottom panels). Analysis was by FACS.
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downregulation by HIV-1 Nef
It has previously been shown that Nef induces CD4
degradation by accelerating endocytosis and MHC class I
relocalization into the trans-Golgi network (Le Gall et al.,
1998; Lu et al., 1998). Distinct portions of the Nef molecule
are responsible for each of these two effects. Human CD1d
molecules contain both a tyrosine-based endosomal targeting
motif and dileucine-like (VL) motif, which direct hCD1d to
compartments of the endocytic pathway (Rodionov et al.,
2000). To ask whether either (or both) of these two motifs are
required for the observed Nef-mediated effects, mutations in
the hCD1d cytoplasmic domain were induced in each of
these sites, including a deletion of the last 6 amino acids,
including both motifs (TD-6). These are shown in Table 1.
The tyrosine residue is important in the intracellular
trafficking of glycoproteins containing the YXXZ motif
(Bonifacino and Dell’Angelica, 1999), and tyrosine 331 is
important for CD1d endocytosis (Rodionov et al., 1999). To
address whether this amino acid is important for the Nef-
mediated downregulation of hCD1d, the Y331 residue was
mutated into Phe (Y331F) or Ala (Y331A). As mentioned
above, the tail region of CD1d also contains a Val-Leu at theC-terminus (Rodionov et al., 2000). A dileucine motif is also
found in the cytoplasmic regions of CD4 and invariant chain,
where it functions as an endocytosis and lysosomal targeting
signal (Bonifacino et al., 1996). Thus, Leu 335 was changed
into Ala (L335A) as well. T2 cells were co-infected with
rVV expressing hCD1d wild-type (WT), Y331F, Y331A,
TD-6, or L335A and rVVexpressing Nef or a control rVVat
an MOI of 5 for 8–12 h. The cell surface levels of these
hCD1d molecules were then examined by flow cytometry.
First, as shown above (i.e., Fig. 2), Nef could efficiently
Fig. 4. The cytoplasmic tail of CD1d is necessary for its reduction on the
cell surface by HIV-1 Nef. (A) Human T2 cells were co-infected with an
rVV expressing wild-type hCD1d or the indicated cytoplasmic tail mutants
with either a control rVV or VV-Nef. Cell surface CD1d molecules were
stained and analyzed as in Fig. 1. The bar graph shows both the mean
fluorescence intensity and percent reduction in hCD1d (wild-type or
mutant) cell surface expression in the presence of a control VV (black bars)
or HIV-1 Nef (white bars). (B) A summary of the individual experiments
performed as in Fig. 4A is shown as a bar graph with error bars. Note that
these experiments were repeated over 10 times.
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4). The cell surface level of the Y331F mutant was as
efficiently downregulated by Nef as was the WT; however, it
is known that F can substitute for Y in the YXXZ motif
(Bonifacino and Dell’Angelica, 1999). Interestingly, the cell
surface expression of a tail-deleted mutant of CD1d (last 6
amino acids deleted; TD-6) was only slightly affected by Nef
(Fig. 4A). Introduction of an alanine in place of the Y331
residue (Y331A) caused less of a decrease in hCD1d
expression by Nef as compared to the wild-type or Y331F
mutant, although not to the same degree as observed in the
TD-6 mutant. Multiple experiments were performed and the
summary of those is indicated as a bar graph with error bars
(Fig. 4B). Other experiments showed that the Y331F/L335A
(YFLA), L335A, and V334A/L335A (AA) double mutantsFig. 5. HIV-1 Nef forms a complex with human CD1d molecules. Human T2 cells w
TD-6-, or TD-10-expressing rVV and a control or Nef-expressing rVV at an MOI o
cleavable cross-linker DSP, lysed, and immunoprecipitated with an anti-hCD1dmAb
SDS–PAGE gel under reducing conditions and immunoblotted with an HRP-conjug
to total lysates from the same cells (WB: Nef; lower blot). The bands were develope
IgG light chain from the anti-CD1d mAb can be detected but distinguished from Nwere inhibited in their cell surface expression to a
comparable degree as the wild-type or Y331F mutant (data
not shown). Therefore, taken together, these data suggest that
the cytoplasmic tail of hCD1d is important for its impaired
cell surface expression in the presence of HIV-1 Nef.
Nef selectively binds the cytoplasmic tail of hCD1d
molecules
Based on the results above, it was asked whether Nef
could form a complex with hCD1d. To test this possibility,
T2 cells were infected with rVV expressing WT, Y331F
(YF), Y331A (YA), L335A (LA), TD-6 or TD-10 hCD1d
molecules, and an rVV expressing Nef (or a control rVV).
The infected cells were then treated with the cell-permeable
cross-linker DSP and immunoprecipitated with an antibody
against hCD1d, followed by Western blotting with an HRP-
conjugated anti-c-myc antibody. In agreement with our
FACS analysis results above, in the case of WT hCD1d, and
the Y331F, Y331A, and L335A mutants, a 31-kDa band
was detected in Nef-containing lysates immunoprecipitated
with the anti-hCD1d antibody but not in lysates containing
control rVV-infected cells (Fig. 5). In contrast, Nef binding
to the TD-6 and TD-10 mutants was almost undetectable.
Thus, the resistance of the tail-deleted hCD1d mutants to be
reduced on the cell surface by HIV-1 Nef could be
explained by its weak binding to Nef relative to WT
hCD1d molecules. The differential binding of Nef to these
hCD1d molecules did not result from varying Nef expres-
sion levels, because the Nef Western blot of whole cell
lysates showed that similar levels of Nef were expressed in
all samples in which Nef was co-expressed with the hCD1d-
encoding rVV (Fig. 5 and data not shown). Thus, these data
suggest that Nef downregulates hCD1d molecules by a
physical association that is dependent on the hCD1d
cytoplasmic tail.
The Nef-mediated reduction in the cell surface expression of
CD1d molecules results in a decrease in the activation of
CD1d-restricted human and murine NKT cells
In order to determine if the reduction in CD1d molecules
by Nef had an effect on the functional expression of CD1d,ere co-infected with CD1dWT-, Y331F (YF)-, Y331A (YA)-, L335A (LA)-,
f 5 for each virus. Eight hours later, the infected cells were treated with the
(42.1) bound to protein G agarose. Immunoprecipitations were run on a 15%
ated anti-c-myc antibody (IP: hCD1d IP;WB: Nef; upper blot) and compared
d by chemiluminescence and exposed on film. Note that in the upper blot, the
ef, as indicated by the arrows.
Fig. 6. HIV-1 Nef inhibits the functional expression of human CD1d
molecules. Human T2 cells were infected overnight with VV-hCD1d and
VV-Nef (or a control VV). The cells were then co-cultured with human
NKT cells for 48 h. The supernatant was harvested and IL-4 production was
measured by ELISA.
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hCD1d with a control rVV or VV-Nef. The cells were then
co-cultured with human NKT cells (Exley et al., 1997).
Expression of hCD1d following infection of T2 cells with
VV-hCD1d and a control VV resulted in NKT cell
recognition. However, when T2 cells were co-infected with
VV-hCD1d and VV-Nef, a substantial reduction in NKT cell
activation was observed (data not shown). Uninfected T2
cells could not be recognized by NKT cells (Fig. 6). These
results suggest that Nef alters the functional expression of
hCD1d. We had found above (Fig. 3) that Nef can reduce
the cell surface level of murine CD1d1. In order to
determine if Nef could affect murine NKT cell recognition
of CD1d1, murine P13.9 fibroblasts were infected with VV-
mCD1d1 and a control VV (or VV-Nef), and co-cultured
with a panel of 3 different murine NKT cell hybridomas. As
observed with human NKT cells, co-expression of mCD1d1
and Nef resulted in a substantial decrease in NKT cell
activation (Fig. 7). Therefore, HIV-1 Nef is able to impair
the functional expression of both human and murine CD1d,
suggesting that it targets a common feature of these two
CD1d homologues.Fig. 7. HIV-1 Nef inhibits the functional expression of murine CD1d1 molecules. M
Nef (or a control VV). The cells were then co-cultured with the murine NKT cell h
were harvested and IL-2 production was measured by ELISA.Discussion
During an HIV infection, Nef decreases the cell surface
expression of MHC class I, class II, and CD4 molecules (Le
Gall et al., 1998; Lu et al., 1998; Stumptner-Cuvelette et al.,
2001). In this study, we found that Nef expression decreased
the cell surface expression of CD1d. Nef, which is
abundantly expressed early during an HIV infection (Reiss
et al., 1989), may have similar effects during an in vivo
infection. The pathway whereby CD1d encounters and
acquires antigens appears to be similar to MHC class II
molecules, although confocal microscopic analysis suggests
that hCD1d molecules, unlike mCD1d, are not abundant in
LAMP-1+ compartments (Moody and Porcelli, 2003). The
cytoplasmic tail of human CD1d contains both tyrosine- and
dileucine-based endocytosis signals (Rodionov et al., 2000).
The current study revealed that a change in the CD1d Y331
residue to an alanine caused a slight resistance to Nef-
mediated downregulation, although an alteration of the
dileucine-like sequence had no effect. In contrast, the
deletion of the cytoplasmic tail of CD1d substantially
reduced its downregulation in the presence of Nef. These
data therefore suggested that Nef might bind to the hCD1d
tail region. In our immunoprecipitation experiments, we
could indeed detect a direct physical association between
Nef and wild-type hCD1d, but this required a cross-linker,
as has been previously shown with MHC class I molecules
(Williams et al., 2002). In addition, Nef did not significantly
bind to the hCD1d TD-6 or TD-10 mutant. Thus, the
association between hCD1d and Nef is weak and/or
transient, with additional factors perhaps necessary to
stabilize a weak complex. Overall, these data suggest that
the tail region of hCD1d is required for Nef binding. It has
also been reported that the HIV-1 protein Vpu can trigger
MHC class I downregulation by inhibiting the cell surface
expression of newly synthesized MHC class I molecules
(Kerkau et al., 1997). Contrary to that found with MHC
class I, Vpu had no effect on hCD1d cell surface expression
(data not shown). It has been recently reported that Nef can
down-modulate CD1a (which is not recognized by NKT
cells) expression on human immature dendritic cells, andurine P13.9 fibroblasts were infected overnight with VV-mCD1d1 and VV-
ybridomas, DN32.D3, N38-3C3, and N37-1A12, for 20 h. The supernatants
S. Cho et al. / Virology 337 (2005) 242–252248there appeared to be no change in CD1d (Shinya et al.,
2004). However, in that report, the level of CD1d in
uninfected cells was very low; thus, any changes in CD1d
on the cell surface would be difficult to discern in their
system. Furthermore, the source strain of the pseudotyped
HIV-1 used in that study was not entirely clear. The
implication is that the Nef used was (as in our study) of
NL4-3 origin. However, it has been reported that although
immature DC can be readily infected with an R5 (use of the
CCR5 chemokine receptor as an HIV-1 entry co-receptor)
strain of HIV-1, they are relatively resistant to infection with
an X4 (CXCR4 chemokine receptor) HIV-1 strain, an
example of which is NL4-3 (Canque et al., 1999).
Recently, several groups have reported that CD4+ NKT
cells are significantly reduced in HIV-1-infected patients as
compared to normal HIV-seronegative controls (Fleuridor et
al., 2003; Motsinger et al., 2002; Sandberg et al., 2002; van
der Vliet et al., 2002). This decline in CD4+ NKT cell
numbers was related to the level of viremia in HIV-infected
patients (van der Vliet et al., 2002). Notably, these NKT cells
have both CD4 and the CXCR4 co-receptors (Sandberg et
al., 2002). The loss of NKT cells in HIV-infected individuals
may have downstream effects on their immune responses.
For example, NKT cells have important effector functions in
both viral and bacterial infections (Gumperz and Brenner,
2001; Nuti et al., 1998), as well as immunoregulatory roles in
the suppression of immune responses against self-antigens
(Godfrey et al., 2000). In the case of effector functions, NKT
cells may play an important role in protection against a
Mycobacterium infection in HIV-infected patients (Barnes et
al., 1991), as several reports suggest that NKT cell-mediated
cytokine production and cytotoxic function against myco-
bacteria are induced through CD1d-mediated mycobacterial
antigen presentation (Chackerian et al., 2002; Emoto et al.,
1999; Gumperz and Brenner, 2001; Saxena et al., 2002).
Also, there is increased tumor development, such as Kaposi’s
sarcoma and non-Hodgkin’s lymphoma in HIV-infected
individuals (Unutmaz, 2003), and several groups have
shown that NKT cells can participate in the antitumor
immune response directly by their cytotoxic activity
(Kawano et al., 1999), and/or indirectly via the secretion of
cytokines, such as IFN-g (Hayakawa et al., 2001). Further-
more, the production of IFN-g and IL-4 by activated NKT
cells can likely affect the Th1 and Th2 balance which could
help or hinder antitumor immune responses, respectively
(Brutkiewicz and Sriram, 2002). Indirectly, NKT cells can
also affect the innate and adaptive antitumor response by
the activation of NK cells and CTL (Carnaud et al., 1999;
Eberl and MacDonald, 2000; Metelitsa et al., 2001;
Nishimura et al., 2000).
As mentioned above, HIV-1 Nef has been reported to be
involved in the downregulation of MHC class I, class II,
and CD4 molecules (Le Gall et al., 1998; Lu et al., 1998;
Stumptner-Cuvelette et al., 2001). CD4 downregulation can
prevent a superinfection during an HIV infection and
inhibit virion release by blocking the function of the viralenvelope (Geleziunas et al., 1994), and MHC class I
downregulation helps HIV-infected cells escape the CTL
response (Collins and Baltimore, 1999; Schubert et al.,
1998). In fact, we have found that the Nef-expressing rVV
induces the generation of a reduced VV-specific CTL
response as compared to a control rVV in a murine model,
consistent with this hypothesis (S. Cho and R. Brutkiewicz,
unpublished observations). Recent reports studying HIV
and NKT cells have not shown whether the HIV-induced
loss of NKT cells has a direct relationship with disease
progression; some studies suggest that there is a preferential
infection of CD4+ NKT cells, whereas others have found
losses in both CD4+ and CD4CD8 subpopulations
(Fleuridor et al., 2003; Motsinger et al., 2002; Sandberg
et al., 2002; van der Vliet et al., 2002). However, our data
clearly demonstrate that HIV-1 Nef impairs the cell surface
expression of human CD1d and forms a complex with it,
suggesting an additional potential mechanism (other than a
direct virus infection) whereby NKT cells could be lost
following an HIV infection—impaired NKT cell activation
due to a reduction in CD1d-mediated antigen presentation
(Figs. 6 and 7). Additional studies are in progress that will
help to further clarify how these mechanisms are important
in the evasion of the host’s innate antiviral immune
response by HIV-1.Materials and methods
Cell lines
P13.9 fibroblasts (kindly provided by R. Germain,
NIAID, NIH, Bethesda, MD), CV-1, and the human 143B
osteosarcoma cell lines were cultured in DMEM supple-
mented with 10% FBS and 2 mM l-glutamine. The human
BxT hybrid T2 cell line (DeMars et al., 1984; Salter and
Cresswell, 1986) was cultured in IMDM supplemented with
5% FBS and 2 mM l-glutamine (I+). The latter three cell
lines were kindly provided by J. Yewdell and J. Bennink
(Laboratory of Viral Diseases, National Institutes of Allergy
and Infectious Diseases, National Institutes of Health,
Bethesda, MD). Human Jurkat T cells were obtained from
the AIDS Research and Reference Reagent Program
(National Institutes of Health, Rockville, MD). The murine
NKT cells, DN32.D3, N37-1A12, and N38-3C3, and their
use in NKT cell assays have been previously described
(Roberts et al., 2002; Sriram et al., 2002). The human NKT
cell line was propagated and co-cultured with human
CD1d+ target cells as previously described (Exley et al.,
1997).
Viruses
The NL4-3 strain of HIV-1 was obtained from Drs. W. C.
Greene and Kalle Saksela (Gladstone Institute, San Fran-
cisco, CA). The wild-type WR strain of vaccinia virus (VV),
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A2.1, and LCMV-NP, were also kindly provided by J.
Yewdell and J. Bennink.
Infection of Jurkat cells with HIV-1
2  106 Jurkat T cells were infected with 1  103
TCID50 of the NL4-3 strain of HIV-1 for 2 h with
constant gentle shaking. Cells were then cultured in T25
tissue culture flasks in RPMI 1640 medium supplemented
with 10% FBS, 2 mM l-glutamine and antibiotics, and
incubated for 8 days at 37 -C. Three Ag/ml of
phytohemagglutinin (PHA; Sigma-Aldrich, St. Louis,
MO) were added for the final 3 days of culture to
augment infectivity. Cells were harvested on day 8 post-
infection and CD1d expression was analyzed by FACS.
The PHA treatment had no effect on CD1d expression in
uninfected cells (data not shown). Active viral infection
was confirmed by p24 levels in the supernatant (>600
pg/ml) as measured by a p24 ELISA kit (sensitivity, 7.5
pg/ml; Coulter, Miami, FL).
Recombinant vaccinia virus (rVV) generation
A c-myc-tagged full-length HIV-1 (NL4-3 strain) Nef
gene (Nef-c-myc) was amplified by PCR using purified
mRNA after a 6-h infection of 143B cells with a recombinant
vaccinia virus (rVV) expressing the HIV-1 strain NL4-3 Nef
cDNA (VV-Nef) obtained from J. Yewdell and J. Bennink
with permission from R. Siliciano (Johns Hopkins Univer-
sity, Baltimore, MD) (Tobery and Siliciano, 1997). The Nef-
c-myc primers were as follows: 5V-ACG TAG TCG ACA
TGG GTG GCA AGT GGT CAA AAA GTA GTG TG-3V
and 5V-ACG TAG CGG CCG CTC ACC GCA ACA AGT
CCT CTT CAG AAATGA GCT TTT GCT CCT CTG CGC
AGT TCT TGA AGT ACT CCG GAT G-3V. The PCR
products were digested with SalI and NotI and were
subcloned into the SalI/NotI sites of pSC11 (Bacik et al.,
1994; Brutkiewicz et al., 1995). hCD1d Y331A (YA),
Y331F (YF), L335A (LA), and V334A (AA) mutants were
made by site-directed PCR mutagenesis of hCD1d in
pBSKII-hCD1d (kindly provided by S. Balk, Beth Israel
Hospital, Harvard Medical School, Boston, MA). The
primers used to generate Y331A were as follows: 5V-TCA
CAG GAC GCC CTG AGC GGA AGT TTG CCT CTT-3V
and 5V-AAG AGG CAA ACT TCC GCT CAG GGC GTC
CTG TGA-3V. The primers used to generate Y331F were 5V-
TCA CAG GAC GCC CTG AAA GGA AGT TTG CCT
CTT-3Vand 5V-AAG AGG CAA ACT TCC TTT CAG GGC
GTC CTG TGA-3V. The primers used to generate Y331F/
L335A (YFLA) were 5V-GTC GGA ACT GAA GAA GCA
AGT GAA GC-3V and 5V-ACG TAG CGG CCG CTC GCG
ATC ACG CGA CGC CCT GAA AGG AAG TTT GCC
TC-3V. The hCD1d tail deleted (TD)-6 (TD-6) mutant was
generated by the introduction of a premature termination
codon through PCR amplification using pBSKII-hCD1d asa template, resulting in the deletion of the last 6 amino
acids in the cytoplasmic tail of hCD1d. The hCD1d TD-10
mutant was made similarly to TD-6, but in this case, the last
10 amino acids of hCD1d were deleted. The primers used
to generate the TD-6 mutant were as follows: 5V-GTC GGA
ACT GAA GAA GCA AGT GAA GC-3V and 5V-ACG
TAG CGG CCG CTC GCG ATC AAG TTT GCC TCT
TAA ACC GGG AGG-3V. The TD-10 reverse primer was
5V-ACG TAG CGG CCG CTC GCG ATC AAA ACC GGG
AGG TAA AGC CCA CAA TG-3V. The reverse primer
used to generate LA was 5V-ACG TAG CGG CCG CTC
GCG ATC ACG CGA CGC CCT GAT AGG AAG TTT
GCC TC 3V, whereas the reverse AA primer was 5V-ACG
TAG CGG CCG CTC GCG ATC ACG CCG CGC CCT
GAT AGG AAG TTT GCC TCC TAA AC-3V. The forward
primer for the latter three mutants was the same as for TD-
6. A unique NruI site not present in either pBSKII or
hCD1d cDNA was engineered into the mutants to assist in
their identification as described previously for the murine
CD1d1 molecule (Roberts et al., 2002). The PCR products
were digested with SalI and NotI, and were subcloned into
the SalI/NotI sites in pSC11 as above. All of the constructs
were analyzed by dideoxynucleotide sequencing to ensure
that the proper mutations were present before the rVVs
were generated. The murine cytomegalovirus m06 gene in
the pACYC184 vector was kindly provided by A. Camp-
bell (Medical College of Virginia, Richmond, VA). m06
was PCR-amplified with a FLAG tag using the following
primers: 5V-ACG TAA GAT CTA TGC CCA GTT GGA
GCG ATA CG-3V and 5V-ACG TAG CGG CCG CTT ACT
TGT CAT CGT CGT CCT TGT AGT CTT T-3V. The PCR
product was digested with BglII and NotI and subcloned
into pSC11. The rVV generation was performed as
previously described (Bacik et al., 1994; Roberts et al.,
2002). Briefly, CV-1 cells were infected for 90 min with
wild-type (WT) VV, followed by the transfection of
infected cells with the appropriate pSC11 vector containing
WT or mutant hCD1d, Nef-c-myc, and m06 cDNA.
Recombinant virus was selected on the basis of bromo-
deoxyuridine (BrdU) resistance and screened by the
detection of h-galactosidase expression as previously
described (Chakrabarti et al., 1985). The recombinant virus
was carried through three rounds of plaque purification in
the presence of BrdU in 143B cells.
Flow cytometry
P13.9 cells or T2 cells were co-infected with rVV
expressing wild-type mCD1d1 or hCD1d, Db or m06, or the
hCD1d mutants and rVV expressing Nef or a control rVV
(VV-LCMV-NP) at a multiplicity of infection (MOI) of 3 to
5 (each virus) for 8–12 h at 37 -C. For HLA-A2.1-staining,
the cells were incubated with the mAb W6/32 (HB-95,
American Type Culture Collection, Manassas, VA), whereas
m06 was stained with a mouse anti-FLAG M2 mAb (Sigma-
Aldrich). Both were followed by a PE-conjugated anti-
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ries, West Grove, PA). For CD1d and CD4 staining, PE-
conjugated anti-mouse or anti-human CD1d mAb, or human
CD4-specific mAb (or appropriate isotype control), was
added to the appropriate cells. Incubation with all antibodies
for FACS was for 30 min on ice. The cells were then fixed
in 1% paraformaldehyde. Antibodies used for flow cytom-
etry (other than those indicated otherwise) were purchased
from Pharmingen (San Diego, CA). After washing three
times in HBSS containing 0.1% BSA and 0.02% azide
(HBSS/BSA), the cells were resuspended in HBSS/BSA
and analyzed using a FACScan cytofluorograph (Becton-
Dickenson, Mountain View, CA).
Immunoprecipitation and Western blot
Following a 24-h infection of T2 cells with rVV
expressing hCD1d WT, Y331A, Y331F, TD-6, TD-10,
YFLA, L335A (LA), or V334A (AA) and VV-Nef-c-myc
(or a control rVV) at an MOI of 5, the cells were treated
with 2 mM Dithiobis(succinimidyl propionate) (DSP)
(Pierce, Rockford, IL) (Story et al., 1999) from a 20-mM
stock in DMSO, and were lysed for 2 h on ice in buffer
containing 1% NP-40, 150 mM NaCl, 20mM Tris–Cl, and
0.5mM EDTA (pH 7.4) with complete protease inhibitor
tablets (Roche, Indianapolis, IN). Lysates were precleared
overnight with normal mouse serum bound to protein A
agarose (Amersham Biosciences, Piscataway, NJ). Immu-
noprecipitations were performed for 2 h with the 42.1 or
51.1 mAb against hCD1d (Exley et al., 2000) bound to
protein G sepharose. Samples were washed three times in
1% NP-40 in Tris-buffered saline (pH 7.6), run on a 15%
SDS–PAGE gel, and then transferred onto a PVDF
membrane. To detect Nef, Western blotting was performed
with a polyclonal HRP-conjugated anti-c-myc Ab (9E10;
Santa Cruz, Santa Cruz, California, CA) and the bands
developed by chemiluminescence (Cell Signaling, Beverly,
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